|
|||||
|
|
| 治疗类风湿性关节炎的选择性 Janus 激酶3抑制药peficitinib | |
| 引用本文： | 王永玲 李汉高. 治疗类风湿性关节炎的选择性 Janus 激酶3抑制药peficitinib[J]. 中国药师, 2019, 0(12): 2267-2269 |
| 作者姓名： | 王永玲 李汉高 |
| 作者单位： | 临朐县人民医院药剂科 山东临朐 262600 |
| 摘 要： | 摘 要Peficitinib是日本安斯泰来制药公司开发的口服小分子选择性Janus激酶3抑制药，于2019年3月在日本获准用于治疗对传统药物反应不佳的类风湿性关节炎成年患者。本文主要描述该药的药效学、药动学、临床疗效和安全性等信息，旨在为临床医生和患者提供参考。 |
| 关 键 词： | Peficitinib；Janus 激酶3；类风湿性关节炎 |
Janus Kinase 3 Selective Inhibitor Peficitinib for the Treatment of Rheumatoid Arthritis |
|
| Wang Yongling,Li Hangao. Janus Kinase 3 Selective Inhibitor Peficitinib for the Treatment of Rheumatoid Arthritis[J]. China Pharmacist, 2019, 0(12): 2267-2269 | |
| Authors: | Wang Yongling Li Hangao |
| Abstract: | ABSTRACT Peficitinib is an orally administered small Janus kinase 3 selective inhibitor developed by Japanese Astellas Pharma. The novel therapeutic agent received its first global approval in March 2019 in Japan for the treatment of rheumatoid arthritis in adult patients with inadequate response to the conventional therapies. The article summarized its information about pharmacodynamics, pharmacokinetics, clinical efficacy and safety to provide good reference for clinicians and patients. |
| Keywords: | Peficitinib Janus kinase 3 Rheumatoid arthritis |
| 点击此处可从《中国药师》浏览原始摘要信息 | |
| 点击此处可从《中国药师》下载全文 | |